Ostatnia aktualizacja :
28/04/2024
Zespoły badawcze - Clinical Pharmacy Department, University Hospital Necker-Enfants Malades   Pdf  
Francja
Szpital
Clinical Pharmacy Department, University Hospital Necker-Enfants Malades
Paris
Bibliografia   Bibliografia   (11)  
1
Pharmaceutical Oral Formulation of Methionine as a Pediatric Treatment in Inherited Metabolic Disease.
Querin B, Schweitzer-Chaput A, Cisternino S, Auvity S, Fauqueur A-S, Negbane A, Hadchouel A, Schlatter J, Cotteret C. (salvatore.cisternino@aphp.fr)
Pharmaceutics - 2023 - ,15, 957.
2
Stability and Formulation of Erlotinib in Skin Creams.
Nguyen D, Secrétan P-H, Cotteret , Jacques-Gustave E, Greco C, Bodemer C, Schlatter J, Cisternino S. (philippe-henri.secretan@u-psud.fr)
Molecules - 2022 - ; 27(3): 1070.
3
Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease.
Hinterlang M, Sebti M, Cotteret C, Vidal F, Neven B, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
The Scientific World Journal - 2022 -
4
Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
El Mershati S, Thouvenin A , Secretan P-H, De Lonlay P, Tuchmann-Durand C, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
Pharm Dev Technol - 2021 -
5
Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags.
Vidal F, Cotteret C, Negbane A, Sebti M, Hinterlang M, Cisternino S, Schlatter J. (joel.schlatter@aphp.fr)
EJHP - 2021 -
6
Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions.
Ancedy D, Sebti M, Postaire M, Vidal F, Cisternino S. ()
Am J Hosp Pharm - 2021 - ;78,9:825–831
7
Voriconazole topical cream formulation: evidence for stability and antifungal activity.
Bouchand C, Nguyen D, Secretan P-H, Vidal F, Guery R, Auvity S, Cohen J.F, Lanternier (joel.schlatter@aphp.fr)
Int J Antimicrob Agents - 2020 - ; 56: 106083.
8
Stability of warfarin sodium flavoured preservative-free oral liquid formulations.
Schlatter J, Cisternino S. (joel.schlatter@ aphp.fr)
EJHP - 2018 - ; 25, e2
9
Physicochemical and Microbiological Stability of Azathioprine in InOrpha Suspending Agent Studied Under Various Conditions.
Amin A, Bourget P, Vidal F, Cartier F, Beauvais R, Do Nascimento Afonso V. ()
Int J Pharm Compound - 2015 - ; 19, 1: 73-77.
10
Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition.
Bourget P, Amin A, Vidal F, Pieyre M, Dosso E.O, Beauvais R, Loeuillet R. ()
Int J Pharm Compound - 2014 - ; 18, 5: 427-431.
11
How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis?
Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R (philippe.bourget@nck.aphp.fr)
Antimicrob Agents Chemother - 2014 - ; 58 : 2849-2855.

Listy   Cząsteczki badane   (11)  
Lek immunosupresyjny Roztwór doustny Azathioprine
Antybiotyk Injekcje Ceftazidime
Lek cytostatyk Maści Erlotinib
Lek przeciwzapalny Roztwór doustny Hydrocortisone
Lek przeciwzapalny Roztwór doustny Hydroxychloroquine sulfate
Znieczulenie ogólne Roztwór doustny Ketamine hydrochloride
Różne Roztwór doustny L-Methionine
Lek cytostatyk Injekcje Pemetrexed diarginine
Lek cytostatyk Roztwór doustny Ruxolitinib
Lek przeciwgrzybiczny Maści Voriconazole
Antykoagulant Roztwór doustny Warfarin sodium

  Mentions Légales